C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus

Clinical Laboratory

Volumn 57, Issue 7-8, 2011, Pages 607-613

  Amezcua Guerra, Luis M ^a   Springall, Rashidi ^a   Arrieta Alvarado, Angel A ^a   Rodríguez, Verónica ^a   Rivera Martinez, Eduardo ^a   Castillo Martinez, Diana ^a   Bojalil, Rafael ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Acute phase reactants; C reactive protein; Complement; Inflammation; Systemic lupus erythematosus

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTITRYPSIN; ANTIMALARIAL AGENT; AZATHIOPRINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT CH50; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLASMA PROTEIN; PREDNISONE; PROCALCITONIN; SALAZOSULFAPYRIDINE; TACROLIMUS; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; ARTHRITIS; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CLINICAL FEATURE; COHORT ANALYSIS; COMPLEMENT SYSTEM; CONTROLLED STUDY; CORRELATION COEFFICIENT; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ACUTE-PHASE PROTEINS; ADULT; ALPHA 1-ANTITRYPSIN; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; ARTHRITIS; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CALCITONIN; COHORT STUDIES; COMPLEMENT SYSTEM PROTEINS; CROSS-SECTIONAL STUDIES; EXANTHEMA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MENTAL DISORDERS; MIDDLE AGED; ORGAN SPECIFICITY; PROTEIN PRECURSORS; TRANSFERRIN; VASCULITIS; YOUNG ADULT;

EID: 80051734667     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Amezcua-Guerra LM, Springall del Villar R, Bojalil Parra R. C-reactive protein: cardiovascular issues of an acute-phase protein. Arch Cardiol Mex 2007;77:58-66. (Pubitemid 46580377)
2. Dayer E, Dayer JM, Roux-Lombard P. Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat Clin Pract Rheumatol 2007;3:512-20. (Pubitemid 47351396)
3. Schiffenbauer J, Hahn B, Weisman MH, Simon LS. Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. Arthritis Rheum 2004;50: 2415-22. (Pubitemid 39062699)
4. Liu CC, Manzi S, Ahearn JM. Biomarkers for systemic lupus erythematosus: a review and perspective. Curr Opin Rheumatol 2005;17:543-9. (Pubitemid 41527813)
5. Amezcua-Guerra LM. Overlap between systemic lupus erythematosus and rheumatoid arthritis: is it real or just an illusion? J Rheumatol 2009;36:4-6.
6. Rodriguez W, Mold C, Marnell LL, et al. Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum 2006;54:325-35. (Pubitemid 43122216)
7. Rodriguez W, Mold C, Kataranovski M, Hurt J, Marnell LL, Du Clos TW. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum 2005;52: 642-50. (Pubitemid 40216331)
8. Szalai AJ, Weaver CT, McCrory MA, et al. Delayed lupus onset in (NZB X NZW)Fl mice expressing a human C-reactive protein transgene. Arthritis Rheum 2003;48:1602-11. (Pubitemid 36682368)
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
10. Gladman DD, Ibáñez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29: 288-91.
11. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39: 363-9. (Pubitemid 26085211)
12. Wintrobe MM, Landsberg JW. A standardized technique for the blood sedimentations test. Am J Med Sci 1935;189:102-14.
13. Mayer MM. Complement and complement fixation. In: Kabat F (ed). Experimental Immunochemistry. Springfield: Charles C. Thomas, 1961:133-240.
14. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 2004;50:1709-20.
15. Karp DR. Complement and systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:538-42. (Pubitemid 41527812)
16. Yang Y, Chung EK, Wu YL, et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 2007;80:1037-54. (Pubitemid 47579341)
17. Meyer OC, Nicaise-Roland P, Cadoudal N, et al. Anti-Clq antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther 2009;11:R87.
18. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. Anti-Clq antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005;64:444-8. (Pubitemid 40283057)
19. Gabay C, Roux-Lombard P, de Moerloose P, Dayer JM, Vischer T, Guerreen PA. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 1993;20: 815-21. (Pubitemid 23158475)
20. ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990;17:1642-8.
21. Amezcua-Guerra LM, Márquez-Velasco R, Bojalil R. Erosive arthritis in systemic lupus erythematosus is associated with high serum C-reactive protein and anti-cyclic citrullinated peptide antibodies. Inflamm Res 2008;57:555-7.
22. Lee SS, Singh S, Link K, Petri M. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008;38: 41-54.
23. Spronk PE, ter Borg EJ, Kallenberg CG. Patients with systemic lupus erythematosus and Jaccoud's arthropathy: a clinical subset with an increased C reactive protein response? Ann Rheum Dis 1992;51:358-61.
24. Williams RC, Harmon ME, Burlingame R, Du Clos TW. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 2005;32:454-61. (Pubitemid 40381415)
25. Jönsen A, Gunnarsson I, Gullstrand B, et al. Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes. Rheumatology (Oxford) 2007;46:1417-21.
26. Szalai AJ, Alarcón GS, Calvo-Alén J, et al. Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford) 2005;44:864-8.
27. Russell AI, Cunninghame Graham DS, Shepherd C, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004;13:137-47. (Pubitemid 38072141)
28. Vogt B, Fuhrnrohr B, Muller R, Sheriff A. CRP and the disposal of dying cells: consequences for systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity 2007;40:295-8. (Pubitemid 46845524)
29. Amezcua-Guerra LM, Castillo-Martinez D, Bojalil R. The story behind the acute-phase reactants. J Rheumatol 2010;37:469-70.